Patents by Inventor Richard E. Olson

Richard E. Olson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Solar antenna array fabrication
    Patent number: 11824264
    Abstract: Methods for constructing multi-walled carbon nanotube (MWCNT) antenna arrays, may include: variable doping of the MWCNTs, forming light pipes with layers of variable dielectric glass, forming geometric diodes on full-wave rectified devices that propagate both electrons and holes, using clear conductive ground plans to form windows that can control a building's internal temperature, and generating multiple lithographic patterns with a single mask.
    Type: Grant
    Filed: May 19, 2022
    Date of Patent: November 21, 2023
    Assignee: NOVASOLIX, INC.
    Inventors: Laurence H. Cooke, Darin S. Olson, Paul Comita, Robert E. Cousins, Albert K. Henning, Andreas Hegedus, David B. Cooke, Yao Te Cheng, John Burke, Richard T. Preston
  • Ice-making device for square cubes using pan partition and pin serpentine evaporators
    Patent number: 11808508
    Abstract: The present disclosure provides an ice making evaporator that combines the cubic shape of pan and partition evaporators with the central ice making of a pin evaporator to achieve an ice shape that is mostly cubic. Separation of the cooling ability of these two evaporator portions allows cube shaping during ice making cycle based on time, temperature, pressure, or other variables.
    Type: Grant
    Filed: February 11, 2021
    Date of Patent: November 7, 2023
    Assignee: PENTAIR FLOW SERVICES AG
    Inventors: William E. Olson, Jr., Richard T. Miller, Timothy L. Hynek, John P. Myers
  • Methods of selecting therapeutic molecules
    Patent number: 11761951
    Abstract: The present disclosure provides methods of using a calcium oscillation assay and/or a sequence score calculation to identify a molecule that is safe for administration. The disclosure also includes a method of selecting or identifying a molecule having tolerable in vivo neurotoxicity using a calcium oscillation assay, a sequence score method, an in vivo tolerability assay, or any combination thereof.
    Type: Grant
    Filed: February 4, 2016
    Date of Patent: September 19, 2023
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Richard E. Olson, Angela M. Cacace, Peter Hagedorn, Anja Mølhart Høg, Niels Fisker Nielsen, Dong LI, Jeffrey M. Brown, Stephen E. Mercer, Marianne Lerbech Jensen
  • Oligonucleotides for modulating Tau expression
    Patent number: 11753640
    Abstract: The present invention relates to antisense oligonucleotides that are capable of modulating expression of Tau in a target cell. The oligonucleotides hybridize to MAPT mRNA. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of Tauopathies, Alzheimzer's disease, fronto-temporal dementia (FTD), FTDP-17, progressive supranuclear palsy (PSP), chronic traumatic encephalopathy (CTE), corticobasal ganglionic degeneration (CBD), epilepsy, Dravet syndrome, depression, seizure disorders and movement disorders.
    Type: Grant
    Filed: December 31, 2020
    Date of Patent: September 12, 2023
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Peter Hagedorn, Anja Mølhart Høg, Richard E. Olson, Marianne L. Jensen
  • PHOSPHOROUS (V)-BASED REAGENTS, PROCESSES FOR THE PREPARATION THEREOF, AND THEIR USE IN MAKING STEREO-DEFINED ORGANOPHOSHOROUS (V) COMPOUNDS
    Publication number: 20230242569
    Abstract: The present invention relates to novel phosphorous (V) (P(V)) reagents, methods for preparing thereof, and methods for preparing organophosphorous (V) compounds by using the novel reagents.
    Type: Application
    Filed: February 10, 2023
    Publication date: August 3, 2023
    Inventors: Michael Anthony SCHMIDT, Bin ZHENG, Kyle KNOUSE, Justine deGRUYTER, Martin D. EASTGATE, Phil BARAN, William R. EWING, Richard E. OLSON, Ivar M. MCDONALD
  • Substituted naphthyridinone compounds useful as T cell activators
    Patent number: 11713316
    Abstract: Disclosed are compounds of Formula (I): or a salt thereof, wherein: R1, R2, R3, R4, R5, and m are defined herein. Also disclosed are methods of using such compounds to inhibit the activity of one or both of diacylglycerol kinase alpha (DGK?) and diacylglycerol kinase zeta (DGK?), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.
    Type: Grant
    Filed: February 1, 2021
    Date of Patent: August 1, 2023
    Assignee: Bristol-Myers Squibb Company
    Inventors: Upender Velaparthi, Louis S. Chupak, Chetan Padmakar Darne, Min Ding, Robert G. Gentles, Yazhong Huang, Manjunatha Narayana Rao Kamble, Scott W. Martin, Raju Mannoori, Ivar M. McDonald, Richard E. Olson, Hasibur Rahaman, Prasada Rao Jalagam, Saumya Roy, Gopikishan Tonukunuru, Sivasudar Velaiah, Jayakumar Sankara Warrier, Xiaofan Zheng, John S. Tokarski, Bireshwar Dasgupta, Kotha Rathnakar Reddy, Thiruvenkadam Raja
  • MULTI-LAYER CURABLE COMPOSITIONS CONTAINING 1,1-DI-ACTIVATED VINYL COMPOUND PRODUCTS AND RELATED PROCESSES
    Publication number: 20230201874
    Abstract: Multi-layer coatings comprising polymerization reaction products of 1,1-di-activated vinyl compounds are described. Also provided are processes for coating substrates with curable compositions comprising 1,1-di-activated vinyl compounds. Also provided are articles coated with this composition.
    Type: Application
    Filed: January 3, 2023
    Publication date: June 29, 2023
    Inventors: Scott J. Moravek, Daniel Connor, Adam B. Powell, Kurt G. Olson, Shanti Swarup, Caroline S. Harris, Davina J. Schwartzmiller, Aditya Gottumukkala, John M. Furar, William E. Eibon, Allison G. Condie, Richard J. Sadvary, Scott W. Sisco, Shiryn Tyebjee
  • ANTISENSE OLIGONUCLEOTIDES TARGETING ALPHA-SYNUCLEIN AND USES THEREOF
    Publication number: 20230193260
    Abstract: The present disclosure relates to antisense oligonucleotides, which target SNCA mRNA (e.g., at an intron exon junction) in a cell, leading to reduced expression of SNCA protein. Reduction of SNCA protein expression is beneficial for the treatment of certain medical disorders, e.g., a neurological disorder.
    Type: Application
    Filed: July 27, 2022
    Publication date: June 22, 2023
    Applicants: Bristol-Myers Squibb Company, Roche Innovation Center Copenhagen A/S
    Inventors: Richard E. OLSON, Angela M. Cacace, Jere E. Meredith, JR., Nino Devidze, James K. Loy, Carl J. Baldick, Annapurna Pendri, Ivar M. McDonald, Peter Hagedorn, Marianne Lerbech Jensen
  • SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS
    Publication number: 20230151007
    Abstract: Disclosed are compounds of Formula (I): or a salt thereof, wherein: R1, R2, R4, R5, and m are defined herein. Also disclosed are methods of using such compounds to inhibit the activity of one or both of diacylglycerol kinase alpha (DGK?) and diacylglycerol kinase zeta (DGK?), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.
    Type: Application
    Filed: November 8, 2022
    Publication date: May 18, 2023
    Inventors: Upender Velaparthi, Richard E. Olson, Chetan Padmakar Darne, Bireshwar Dasgupta, Jayakumar Sankara Warrier, Hasibur Rahaman, Prasada Rao Jalagam, Saumya Roy, Denise Christine Grunenfelder
  • SUBSTITUTED PIPERAZINE DERIVATIVES USEFUL AS T CELL ACTIVATORS
    Publication number: 20230118629
    Abstract: Disclosed are compounds of Formula (I): or a salt thereof, wherein: R1, R2, R4, R5, R6, and m are defined herein. Also disclosed are methods of using such compounds to inhibit the activity of one or both of diacylglycerol kinase alpha (DGK?) and diacylglycerol kinase zeta (DGK?), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferatve disorders, such as cancer.
    Type: Application
    Filed: December 22, 2020
    Publication date: April 20, 2023
    Inventors: Upender Velaparthi, Chetan Padmakar Darne, Richard E. Olson, Jayakumar Sankara Warrier
  • SUBSTITUTED QUINAZOLINYL COMPOUNDS USEFUL AS T CELL ACTIVATORS
    Publication number: 20230094758
    Abstract: Disclosed are compounds of Formula (I): (I) or a salt thereof, wherein: R1, R2, R4, R5, R6, and m are defined herein. Also disclosed are methods of using such compounds to inhibit the activity of one or both of diacylglycerol kinase alpha (DGK?) and diacylglycerol kinase zeta (DGK?), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.
    Type: Application
    Filed: December 22, 2020
    Publication date: March 30, 2023
    Inventors: Upender Velaparthi, Richard E. Olson, Jayakumar Sankara Warrier, Hasibur Rahaman
  • Phosphorous (V)-based reagents, processes for the preparation thereof, and their use in making stereo-defined organophoshorous (V) compounds
    Patent number: 11613554
    Abstract: The present invention relates to novel phosphorous (V) (P(V)) reagents, methods for preparing thereof, and methods for preparing organophosphorous (V) compounds by using the novel reagents.
    Type: Grant
    Filed: April 12, 2019
    Date of Patent: March 28, 2023
    Assignees: Bristol-Myers Squibb Company, The Scripps Research Institute
    Inventors: Michael Anthony Schmidt, Bin Zheng, Kyle Knouse, Justine deGruyter, Martin D. Eastgate, Phil Baran, William R. Ewing, Richard E. Olson, Ivar M. McDonald
  • SUBSTITUTED HETEROARYL COMPOUNDS USEFUL AS T CELL ACTIVATORS
    Publication number: 20230086933
    Abstract: Disclosed are compounds of Formula (I): (I) or a salt thereof, wherein: X is CR6 or N; Y is CR3 or N; R1, R2, R3, R4, R5, R6, and m are defined herein. Also disclosed are methods of using such compounds to inhibit the activity of one or both of diacylglycerol kinase alpha (DGK?) and diacylglycerol kinase zeta (DGK?), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.
    Type: Application
    Filed: December 22, 2020
    Publication date: March 23, 2023
    Inventors: Upender Velaparthi, Chetan Padmakar Darne, Richard E. Olson, Prasada Rao Jalagam, Jayakumar Sankara Warrier
  • COMBINATIONS OF DGK INHIBITORS AND CHECKPOINT ANTAGONISTS
    Publication number: 20230089255
    Abstract: Provided are inhibitors of diacylglycerol kinases (DGK) and methods for treating diseases that would benefit from the stimulation of the immune system, such as cancer and infections diseases, comprising administering a DGK inhibitor in combination with an antagonist of the PD 1/PD-L 1 axis and/or an antagonist of CTLA4.
    Type: Application
    Filed: December 18, 2020
    Publication date: March 23, 2023
    Inventors: Susan WEE, Joseph L. BENC, Xinyu WANG, Upender VELAPARTHI, Louis S. CHUPAK, Chatan P. DARNE, Min DING, Robert G. GENTLES, Yazhong HUANG, Scott W. MARTIN, Ivar M. MCDONALD, Richard E. OLSON, Xiaofan ZHENG, John S. TOKARSKI, Bireshwar DASGUPTA, Manjunatha Narayana Rao KAMBLE, Raju MANNOORI, Haslbur RAHAMAN, Prasada Rao JALAGAM, Saumya ROY, Gopikishan TONUKUNURU, Sivasudar VELAIAH, Jayakumar Sankara WARRIER, Kotha Rathnakar REDDY, Thiruvenkadam RAJA, Denise GRUNENFELDER, Michael WICHROSKI
  • SUBSTITUTED QUINOLINONYL PIPERAZINE COMPOUNDS USEFUL AS T CELL ACTIVATORS
    Publication number: 20230061608
    Abstract: Disclosed are compounds of Formula (I) or a salt thereof, wherein: R1, R2, R3, R4, R5, R6, and m are defined herein. Also disclosed are methods of using such compounds to inhibit the activity of one or both of diacylglycerol kinase alpha (DGK?) and diacylglycerol kinase zeta (DGK?), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.
    Type: Application
    Filed: December 22, 2020
    Publication date: March 2, 2023
    Inventors: Louis S. Chupak, Richard E. Olson, Upender Velaparthi, Xiaofan Zheng, Robert G. Gentles, Min Ding, Jayakumar Sankara Warrier
  • Substituted pyridopyrimidinonyl compounds useful as T cell activators
    Patent number: 11584747
    Abstract: Disclosed are compounds of Formula (I): or a salt thereof, wherein: R1, R2, R4, R5, and m are defined herein. Also disclosed are methods of using such compounds to inhibit the activity of one or both of diacylglycerol kinase alpha (DGK?) and diacylglycerol kinase zeta (DGK?), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.
    Type: Grant
    Filed: August 27, 2020
    Date of Patent: February 21, 2023
    Inventors: Upender Velaparthi, Richard E. Olson, Chetan Padmakar Darne, Bireshwar Dasgupta, Jayakumar Sankara Warrier, Hasibur Rahaman, Prasada Rao Jalagam, Saumya Roy, Denise Christine Grunenfelder
  • SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS
    Publication number: 20220324859
    Abstract: Disclosed are compounds of Formula (I): or a salt thereof, wherein: R1, R2, R3, R4, R5, and m are defined herein. Also disclosed are methods of using such compounds to inhibit the activity of one or both of diacylglycerol kinase alpha (DGK?) and diacylglycerol kinase zeta (DGK?), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.
    Type: Application
    Filed: February 1, 2021
    Publication date: October 13, 2022
    Inventors: Upender Velaparthi, Louis S. Chupak, Chetan Padmakar Darne, Min Ding, Robert G. Gentles, Yazhong Huang, Manjunatha Narayana Rao Kamble, Scott W. Martin, Raju Mannoori, Ivar M. McDonald, Richard E. Olson, Hasibur Rahaman, Prasada Rao Jalagam, Saumya Roy, Gopikishan Tonukunuru, Sivasudar Velaiah, Jayakumar Sankara Warrier, Xiaofan Zheng, John S. Tokarski, Bireshwar Dasgupta, Kotha Rathnakar Reddy, Thiruvenkadam Raja
  • Antisense oligonucleotides targeting alpha-synuclein and uses thereof
    Patent number: 11447775
    Abstract: The present disclosure relates to antisense oligonucleotides, which target SNCA mRNA (e.g., at an intron exon junction) in a cell, leading to reduced expression of SNCA protein. Reduction of SNCA protein expression is beneficial for the treatment of certain medical disorders, e.g., a neurological disorder.
    Type: Grant
    Filed: January 11, 2019
    Date of Patent: September 20, 2022
    Assignees: Bristol-Myers Squibb Company, Roche Innovation Center Copenhagen A/S
    Inventors: Richard E. Olson, Angela M. Cacace, Jere E. Meredith, Jr., Nino Devidze, James K. Loy, Carl J. Baldick, Annapurna Pendri, Ivar M. McDonald, Peter Hagedorn, Marianne Lerbech Jensen
  • ANGPTL2 ANTISENSE OLIGONUCLEOTIDES AND USES THEREOF
    Publication number: 20220213484
    Abstract: The present disclosure relates to antisense oligonucleotides, which target ANGPTL2 mRNA in a cell, leading to reduced expression of ANGPTL2 protein. Reduction of ANGPTL2 protein expression is beneficial for the treatment of certain medical disorders, such as those associated with abnormal ANGPTL2 expression and/or activity e.g., cardiovascular-related diseases or disorders.
    Type: Application
    Filed: April 2, 2020
    Publication date: July 7, 2022
    Inventors: Brian R. ANDERSON, Richard E. OLSON, Ivar M. MCDONALD, Stephen E. MERCER, Peter HAGEDORN, Marianne Lerbech JENSEN
  • Antisense oligonucleotides targeting alpha-synuclein and uses thereof
    Patent number: 11359197
    Abstract: The present disclosure relates to antisense oligonucleotides, which target SNCA mRNA (e.g., at an intron exon junction) in a cell, leading to reduced expression of SNCA protein. Reduction of SNCA protein expression is beneficial for the treatment of certain medical disorders, e.g., a neurological disorder.
    Type: Grant
    Filed: February 2, 2021
    Date of Patent: June 14, 2022
    Assignee: Bristol-Myers Squibb Company
    Inventors: Richard E. Olson, Angela M. Cacace, Jere E. Meredith, Jr., Nino Devidze, James K. Loy, Carl J. Baldick, Annapurna Pendri, Ivar M. McDonald, Peter Hagedorn, Marianne Lerbech Jensen